Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2026 (Specifically September 2–3, 2026)
Context: The filing details an inducement transaction to encourage the exercise of existing warrants by a specific holder, resulting in new capital raises and the issuance of new warrants.
Key Financial Metrics
- Expected Gross Proceeds: Approximately $4.0 million from the exercise of existing warrants.
- Transaction Volume: Exercise of 1,591,738 American Depositary Shares (ADSs).
- Reduced Exercise Price: $2.50 per ADS (reduced from the original $5.00 per ADS).
- Placement Agent Fees:
- Cash fee: 7.0% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Non-accountable expenses: $75,000.
- Clearing fees: $15,950.
- Placement Agent Warrants: 111,422 ADSs at an exercise price of $3.125 per ADS.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these general financial metrics; it focuses solely on the specific warrant transaction.
Material Changes and Transaction Details
The Company entered into an Inducement Letter with a holder of existing warrants issued on March 5, 2026. Key changes include:
- Price Reduction: The exercise price for the existing warrants was reduced from $5.00 to $2.50 per ADS to induce cash exercise.
- New Warrant Issuance: In consideration for the exercise, the Company issued new warrants to purchase up to 3,183,476 ADSs (2x the number of shares exercised) at an exercise price of $2.50 per ADS.
- Use of Proceeds: Net proceeds are designated for funding research and development, clinical trials, working capital, and general corporate purposes.
- Lock-up Provisions: The Company agreed not to issue new ADSs or file new registration statements for 30 days post-closing and not to effect Variable Rate Transactions for one year post-closing.
Guidance, Outlook, and Risks
- Closing Date: Expected on or about September 3, 2026, subject to customary closing conditions.
- Registration: The Company must file a Resale Registration Statement (Form F-3) for the new warrant shares and use commercially reasonable efforts to have it declared effective within 90 days.
- Liquidity Risk: There is no established trading market for the New Warrants, and the Company does not expect an active market to develop, resulting in extremely limited liquidity for these instruments.
- Forward-Looking Statements: The closing is contingent on conditions; failure to satisfy these conditions may prevent the transaction from closing.
- Ownership Caps: Holders cannot exercise warrants if it results in ownership exceeding 4.99% (or 9.99% with notice) of outstanding ordinary shares.
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $4.0 million gross proceeds receipt.
- Confirm the effective date of the Resale Registration Statement for the New Warrant Shares.
- Review the impact of the 2:1 warrant issuance ratio (3,183,476 new warrants for 1,591,738 shares exercised) on potential future dilution.
- Monitor the Company's cash burn rate relative to the new capital raised for R&D and clinical trials.
- Check for any subsequent filings regarding the 30-day lock-up period on new issuances.